HematoCARD: A Volumetric Duplicate Dried Blood Spot Collection Cartridge Validated for Therapeutic Drug Monitoring
Van Hileghem et al.
The finding, in our words
The HematoCARD cartridge autonomously collects duplicate 10 microlitre dried blood spot samples from a single finger prick and shows good analytical performance for monitoring adalimumab, with accuracy between 91 and 111 per cent, linearity R squared 0.99 and coefficient of variation at or above 0.94 compared with serum reference and commercial DBS microsampling methods.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This review found that volumetric microsampling devices, such as Mitra, HemaPEN, HemaXis DB10, and Tasso-M20, overcome haematocrit bias, whilst Telimmune plasma separation cards enable direct plasma collection without centrifugation. These technologies support patient-centric, decentralised sampling, though the authors note that clinical validation remains limited across different drugs and patient populations.
An LC-MS/MS method for dried blood spots simultaneously quantifies four therapeutic monoclonal antibodies and estimates haematocrit from haemoglobin peptides with >0.9 correlation to laboratory values, enabling accurate therapeutic drug monitoring from self-collected samples for decentralised care.
A microfluidic DBS device using hydrophobic burst valves meters 5-15 μL blood accurately across 25-70% haematocrit and, in a therapeutic drug monitoring validation with adalimumab-spiked samples, achieves higher recovery than traditional DBS (86% versus 62%), supporting precise home or low-resource sampling.
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
Volumetric microsampling can enable patient-centred therapeutic drug monitoring with high patient preference and acceptable method validation for many drugs, but conversion from capillary to plasma and agreement with venous sampling varies by analyte and requires careful validation.